In in vitro and in vivo NAFLD models, MEG3 downregulation is negatively correlated with lipogenesis-related genes, and MEG3 overexpression mitigates excessive lipid accumulation in HepG2 cells. Here, MEG3 is linked to metabolic dysfunction-associated steatotic liver disease.